---
category: news
title: "Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics,"
publishedDateTime: 2021-01-04T06:00:00Z
originalUrl: "https://www.morningstar.com/news/pr-newswire/20210104da36411/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-blood-cancers-through-agreement-with-califia-pharma"
webUrl: "https://www.morningstar.com/news/pr-newswire/20210104da36411/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-blood-cancers-through-agreement-with-califia-pharma"
type: article

provider:
  name: Morningstar, Inc.
  domain: morningstar.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg"
    width: 400
    height: 296
    isCached: true

secured: "B2FsKvfNt1AY1CejJqDlqX0Rd6HWbHWFpYcoZq07Xh/G3BQppbX5OEz/IMaBMDDWo4Ki1ZWTQLMXhwHOuT9ijBFTSvMU72o/X7IPsUQsV1FTZ8M/ADmD6I2bJ+7Yn0Haq3qglJVq+X4row+G9aNmpFL7jUFaUNrn5rrm0yzdqCZEc2ox2mEra3o97DMqma86080HGJV7scsf1p2beZjfRh8sALg2RzH0Un72SUy+MbzIWuBiQrUFSffLvCKGJ/EAdJytV9l4lSx3pySh+/LuEi8DQBnzphpXdqJXP/pemVaDjzF8zlTB+2wJ+dwxRQWNWHEEDHbbjjF12C7j+kssCIs/PQNPFOaW2dfcO6OP4Ps=;w0OdWVkcF6RaVO/brMMuLg=="
---

